Spun out of the University of Toronto, the young start-up looked to Silicon Valley and corporate pharma investors for capital.

Evidence of progress for molecular diagnostics and instrumentation, the mainstays of the personalized medicine toolkit, was considerable in 2010. Much of the activity centered on sequencing, although its general utility in clinical diagnostics has not yet been demonstrated and whether measurements of gene expression can form the basis for a plethora of molecular tests also remains an open question. In abbreviated form, we list some of the important dealmaking activities and trends of the year.

Evidence of progress for molecular diagnostics and instrumentation, the mainstays of the personalized medicine toolkit, was considerable in 2010. Much of the activity centered on sequencing, although its general utility in clinical diagnostics has not yet been demonstrated and whether measurements of gene expression can form the basis for a plethora of molecular tests also remains an open question. In abbreviated form, we list some of the important dealmaking activities and trends of the year.